
Positive results for cannabinoid targeting multi-billion pain market
Oxford Cannabinoid Technologies has stated it will begin Phase I clinical trials early next year.

Oxford Cannabinoid Technologies has stated it will begin Phase I clinical trials early next year.

The company stated it reached a significant milestone last year.

THC beverages are growing in popularity driven by a shift away from alcohol.

Patients will now be able to access Kanabo’s medical cannabis and CBD products through The GP Service (GPS).

The UK-based CBD brand will out the funds towards streamlining the business.

Canxchange explores how a lack of coherent price indexing for hemp affects the commodity’s prices.

The legalisation of cannabis has been a boon for the financial industry, says new study.

New Frontier Data has released its latest industry report exploring predictions for the year to come.

A new report has projected the market to exceed $310m by 2027.

Canxchange is introducing more transparency, liquidity and efficiency to the growing cannabis market through its new platform.
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
© 2023 Prohibition Holdings Ltd. All Rights Reserved.